As icu intensivist how to adjust the Dose of different types of insulins in ICU setting for patient have high sugars start from basic to advanced include dosage, duration, common brands used complete detailed picture
Reading File
Finding Sources
Finding Sources
Searching PubMed
"insulin" AND "intensive care" AND "glycemic control" AND "protocol"
Finding Sources
Finding Sources
Searching PubMed
"insulin" AND "critical care" AND "hyperglycemia"
Finding Sources
Finding Sources
Reading Article
Reading File
Finding Sources
Searching the Web
ICU insulin protocol types dosing titration guidelines 2024 intensivist hyperglycemia management
Reading File
Reading Web Page
insulin types dosing ICU protocol titration
Reading File
Finding Sources
I now have comprehensive information from authoritative sources. Let me compile the full detailed answer.
ICU Insulin Management: Complete Guide for the Intensivist
Why Insulin in the ICU Demands Special Attention
Critical illness triggers stress hyperglycemia through catecholamine release, glucocorticoid surge, cytokine-mediated insulin resistance, and exogenous dextrose/nutrition loads. Both diabetic and non-diabetic patients are affected. Hyperglycemia in ICU patients is independently associated with increased mortality, wound infections, prolonged ventilation, polyneuropathy, and renal failure.
Part 1: Targets - What Are You Aiming For?
SCCM 2024 Guidelines (PMID: 38240484)
| Population | Trigger to Treat | Glucose Target |
|---|---|---|
| Critically ill adults | Persistent BG >= 180 mg/dL (10 mmol/L) | 140-180 mg/dL (7.8-10 mmol/L) |
| Surgical/cardiac ICU | >= 180 mg/dL | 140-180 mg/dL (some centers 110-140) |
| Avoid | --- | < 110 mg/dL (intensive insulin therapy increases mortality/hypoglycemia - NICE-SUGAR) |
Key principle: The panel recommends against intensive glycemic targets (80-110 mg/dL). The goal is preventing harm from hyperglycemia while avoiding hypoglycemia.
Part 2: Types of Insulin Used in the ICU
Tier 1 - IV Insulin (Preferred in Critical Care)
Regular Human Insulin is the gold standard for IV infusions in the ICU.
| Parameter | Details |
|---|---|
| Brands | Humulin R (Eli Lilly), Novolin R (Novo Nordisk) |
| Onset (IV) | Immediate (< 1 minute) |
| Peak (IV) | 15-30 minutes |
| Duration (IV) | 30-60 minutes |
| IV preparation | 100 units in 100 mL NS (1 unit/mL) - standard concentration |
| Why preferred | Rapid titration, predictable, short half-life, allows fine-tuned control |
Both insulin aspart (NovoLog/NovoRapid) and insulin glulisine (Apidra) are also approved for IV infusion, but regular insulin remains the most commonly used due to cost, familiarity, and established protocols. (Texas DSHS ICU Protocol)
Tier 2 - Subcutaneous Insulin (Step-Down / Non-Critical Settings)
Once the patient is stable and transitioning out of the ICU, switch to subcutaneous regimens.
Rapid-Acting Analogues (for bolus/correction doses)
| Insulin | Brand(s) | Onset SC | Peak SC | Duration SC | Notes |
|---|---|---|---|---|---|
| Insulin lispro | Humalog, Admelog | 10-15 min | 30-90 min | 3-5 h | Most widely used rapid-acting |
| Insulin aspart | NovoLog, NovoRapid, Fiasp | 10-20 min | 40-50 min | 3-5 h | Can be used IV |
| Insulin glulisine | Apidra | 10-15 min | 30-90 min | 3-5 h | Can be used IV |
Short-Acting (Regular)
| Insulin | Brand(s) | Onset SC | Peak SC | Duration SC | Notes |
|---|---|---|---|---|---|
| Regular insulin | Humulin R, Novolin R | 30-60 min | 2-4 h | 6-8 h | Used for enteral feeding coverage, tube feeds |
Intermediate-Acting
| Insulin | Brand(s) | Onset SC | Peak SC | Duration SC | Notes |
|---|---|---|---|---|---|
| NPH (Neutral Protamine Hagedorn) | Humulin N, Novolin N | 1-3 h | 4-8 h | 12-18 h | Used for enteral tube feeding (nocturnal/cycled feeds) |
Long-Acting Basal Analogues (for ICU-to-ward transition)
| Insulin | Brand(s) | Onset SC | Peak SC | Duration SC | Notes |
|---|---|---|---|---|---|
| Glargine U-100 | Lantus, Basaglar | 1-2 h | Peakless | 20-24 h | Most used basal for ICU transition |
| Glargine U-300 | Toujeo | 1-2 h | Peakless | > 24 h | Flatter profile, less hypoglycemia |
| Detemir | Levemir | 1-2 h | Relatively flat | 18-24 h | Dose 25% higher than glargine if switching |
| Degludec U-100/U-200 | Tresiba | Gradual | Ultra-flat | > 42 h | Ultra-long, very stable - good for insulin resistance |
Part 3: ICU IV Insulin Infusion Protocol (Step-by-Step)
Step 1 - Preparation of Drip
Standard concentration: 100 units regular insulin in 100 mL 0.9% NaCl = 1 unit/mL
Flush the IV tubing with 20-30 mL of the solution before connecting to patient (insulin binds to PVC tubing).
Step 2 - Initial Bolus and Starting Rate
Formula: Divide initial glucose by 100, round to nearest 0.5 units
| Initial Glucose | IV Bolus | Starting Infusion Rate |
|---|---|---|
| 180-250 mg/dL | 1.5-2 units | 1.5-2 units/h |
| 251-300 mg/dL | 2.5-3 units | 2.5-3 units/h |
| 301-360 mg/dL | 3-3.5 units | 3-3.5 units/h |
| > 360 mg/dL | 3.5-4 units | 3.5-4 units/h |
Example: Glucose 326 mg/dL - 326 / 100 = 3.26, round to 3.5 - Give 3.5 units IV bolus + start infusion at 3.5 units/h
Step 3 - Titration Algorithms (Texas DSHS Protocol, 4-Algorithm System)
Algorithm selection by insulin resistance:
| Algorithm | Patient Profile | Example Rates (at 180-209 mg/dL) |
|---|---|---|
| Algorithm 1 | No prior diabetes, low insulin needs | 2 units/h |
| Algorithm 2 | Known DM, post-cardiac surgery, steroids | 3 units/h |
| Algorithm 3 | High insulin resistance, inadequate control on Alg 2 | 5 units/h |
| Algorithm 4 | Refractory - requires endocrine consultation | 9 units/h |
Move UP (to higher algorithm) when: Glucose remains above target after titrating within current algorithm
Move DOWN (to lower algorithm) when: BG < 70 mg/dL x2, or BG drops > 60 mg/dL in 1 hour
Step 4 - Titration Rules Within an Algorithm
| BG (mg/dL) | Action |
|---|---|
| < 70 | Stop infusion, give D50W 25 mL IV, recheck in 15 min |
| 70-109 | Reduce rate (Algorithm-specific) |
| 110-140 | Continue at current rate |
| 141-180 | Slight increase (0.5-1 unit/h) |
| 181-240 | Increase by 1-2 units/h |
| > 240 | Increase by 2-3 units/h, consider bolus |
Step 5 - Monitoring Frequency
| Situation | Glucose Check Frequency |
|---|---|
| Starting infusion / BG unstable | Every 1 hour (SCCM 2024: <= 1 hour intervals during instability) |
| BG in target x 4 consecutive hours | Every 2 hours |
| Stable on infusion x 4 hours more | Every 4 hours |
| Patient on continuous glucose monitor (CGM) | CGM + hourly POC during instability |
Part 4: Special ICU Scenarios
A. DKA in the ICU
(Washington Manual, p. 890)
| Step | Action |
|---|---|
| IV fluids | 0.9% NS 1L bolus, then 500-1000 mL/h |
| Insulin start | Wait until K+ > 3.5 mEq/L |
| Insulin bolus | 0.1 units/kg IV regular insulin |
| Insulin infusion | 0.1 units/kg/h |
| Target BG drop | 50-75 mg/dL/h (avoid > 100 mg/dL/h - risk cerebral edema) |
| When BG < 250 mg/dL | Add D5W separately ("two-bag" approach), reduce insulin to 0.05 units/kg/h |
| Continue infusion until | HCO3 > 15 mEq/L, anion gap closed, clinical improvement |
| Transition | Give SC basal insulin 2 hours before stopping infusion |
B. Hyperglycemic Hyperosmolar State (HHS)
- IV regular insulin infusion at 0.05-0.1 units/kg/h (lower than DKA - more sensitive)
- Target BG drop: 50-75 mg/dL/h
- Large volume fluid resuscitation is the primary intervention
- Add glucose infusion when BG < 300 mg/dL
C. TPN-Associated Hyperglycemia
(Harrison's 22E) IV insulin infusion is preferred for TPN-associated hyperglycemia. Rapid dose titration is best done with a separate insulin infusion (not by adding insulin directly to the TPN bag). Once the daily dose is established, insulin can be incorporated into the TPN bag.
D. Enteral Nutrition/Tube Feeds
(Washington Manual, p. 888)
| Feed Type | Insulin Strategy |
|---|---|
| Intermittent bolus feeds | Regular insulin SC (to match feed timing) |
| Continuous tube feeds | Rapid-acting insulin SC q4-6h OR Regular insulin q6h |
| Nighttime cyclic feeds (6-8h) | NPH SC to cover the feeding window |
| Baseline hyperglycemia on top | Add basal insulin in addition |
E. Steroid-Induced Hyperglycemia
- Glucocorticoids impair insulin secretion, increase hepatic glucose production, worsen resistance
- Pattern: predominantly postprandial or afternoon/evening hyperglycemia
- Management: Start with NPH insulin timed to steroid dose (if once-daily steroids), or add prandial rapid-acting insulin
- May require 50-100% more insulin than usual
F. Post-Cardiac Surgery / Solid Organ Transplant
- Start on Algorithm 2 minimum (higher insulin resistance expected)
- Target 110-150 mg/dL (some protocols 110-140) in perioperative cardiac surgery
- Continuous glucose monitoring emerging as useful adjunct
Part 5: Transitioning from IV to Subcutaneous Insulin (ICU to Step-Down)
This is one of the most error-prone steps. A premature or miscalculated transition causes rebound hyperglycemia.
Rules:
- Give SC basal insulin at least 2 hours before stopping the IV infusion (overlap period)
- Estimate total daily dose (TDD) from the infusion
TDD Calculation
TDD (units/day) = Infusion rate (units/h) × 20 hours
(20h used rather than 24h to account for a safety margin)
Dose Distribution
| Patient Status | Basal | Prandial/Bolus | Bridging Dose |
|---|---|---|---|
| Eating | 50% of TDD as glargine/detemir | 50% TDD divided by 3 meals (rapid-acting) | 10% of basal dose once |
| NPO/TPN/Tube Feed | 100% TDD as basal | --- | 5% of basal dose once |
Example: Patient has been on insulin infusion at 3 units/h
- TDD = 3 × 20 = 60 units
- If eating: 30 units glargine + 10 units lispro/aspart TID with meals + 3 unit bridging dose at transition
- If NPO: 60 units glargine + 3 unit bridging dose
Important notes on basal selection:
- Glargine is preferred (Lantus/Basaglar) - once daily, peakless
- If switching to detemir: use 25% higher dose than glargine would be
- If using NPH as basal: give 2/3 of TDD bid (2/3 morning, 1/3 bedtime), can divide q6h
Part 6: Hypoglycemia Prevention and Management
| Severity | BG | Action |
|---|---|---|
| Mild (asymptomatic) | 54-70 mg/dL | Reduce/hold infusion, give D50W 25 mL IV, recheck in 15 min |
| Moderate | 40-54 mg/dL | Stop infusion, D50W 50 mL IV, recheck q15 min |
| Severe | < 40 mg/dL | Stop infusion, D50W 50-100 mL IV, glucagon 1 mg IM if no IV access, recheck q15 min |
| Target | Recheck until BG > 100 mg/dL and stable |
After any hypoglycemia: Step down to lower algorithm, reassess insulin needs, evaluate for precipitants (reduced feeds, renal failure worsening, hepatic impairment).
Part 7: Insulin-Naïve vs. Known Diabetic Patient - Starting Doses
(Washington Manual, p. 888)
New-Start Subcutaneous Insulin (non-ICU floors, step-down)
| Patient | Basal Starting Dose | Prandial Starting Dose |
|---|---|---|
| Insulin-naive | 0.1-0.2 units/kg/day glargine | 0.1-0.2 units/kg divided by 3 meals |
| Known T2DM (admitted) | Reduce home dose by 20% | Match prandial to meals |
| Known T1DM | Continue home doses | Continue home pump if policy allows |
80 kg example (insulin-naive): 8-16 units glargine daily + 3-5 units rapid-acting before each meal + correction 1-2 units per 50 mg/dL above 140 mg/dL
When to escalate correction factor:
- If correction doses needed >= 3 times/day: increase basal by 10-20%
- If fasting BG persistently > 180: increase basal
- If post-meal BG persistently > 180: increase prandial dose
Part 8: Quick Reference Summary Table
| Insulin Type | Brand Examples | Route in ICU | Onset | Duration | Primary ICU Use |
|---|---|---|---|---|---|
| Regular (IV) | Humulin R, Novolin R | IV infusion | < 1 min | 30-60 min | 1st line ICU infusion |
| Aspart (IV) | NovoLog, Fiasp | IV infusion | < 1 min | ~30 min | Alternative IV infusion |
| Glulisine (IV) | Apidra | IV infusion | < 1 min | ~30 min | Alternative IV infusion |
| Lispro (SC) | Humalog, Admelog | SC | 10-15 min | 3-5 h | Post-ICU prandial |
| Aspart (SC) | NovoLog | SC | 10-20 min | 3-5 h | Post-ICU prandial |
| Regular (SC) | Humulin R | SC | 30-60 min | 6-8 h | Enteral feeds, tube feeds |
| NPH | Humulin N, Novolin N | SC | 1-3 h | 12-18 h | Cyclic tube feeds |
| Glargine U-100 | Lantus, Basaglar | SC | 1-2 h | 20-24 h | Primary basal at transition |
| Glargine U-300 | Toujeo | SC | 1-2 h | > 24 h | High resistance, stable patients |
| Detemir | Levemir | SC | 1-2 h | 18-24 h | Alternative basal (dose 25% higher) |
| Degludec | Tresiba | SC | Gradual | > 42 h | Ultra-long coverage |
Key Evidence Reminders
- NICE-SUGAR Trial (NEJM 2009): Intensive insulin therapy (80-110 mg/dL) increased 90-day mortality vs. conventional (140-180 mg/dL). The era of "tighter is better" is over.
- SCCM 2024 Guidelines (PMID: 38240484): Recommend insulin infusion for acute ICU hyperglycemia, with an explicit clinical decision support tool, monitoring every <= 1 hour during instability. Against intensive glucose targets.
- Sliding scale insulin alone is insufficient and inferior to basal-bolus-correction regimens for inpatient glycemic control.
- Avoid premixed insulins (70/30) in the ICU - absorption is unpredictable and dosing flexibility is lost.
Sources: Washington Manual of Medical Therapeutics (9781975190620), p. 888-890 | Harrison's Principles of Internal Medicine 22E | SCCM 2024 Guidelines (PMID: 38240484) | Texas DSHS ICU Insulin Infusion Protocol | US Pharmacist Clinical Review
This is a shared conversation. Sign in to Orris to start your own chat.